Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma

INTRODUCTION: Recent introduction of immuno‐oncology drugs such as pembrolizumab has resulted in improved outcomes for urothelial carcinoma patients. However, immune‐related adverse events generally show great variance and are often difficult to diagnose and control. CASE PRESENTATION: An 84‐year‐ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Yamanaka, Kazuaki, Tadokoro, Rei, Wakita, Teppei, Fukae, Shota, Yoshida, Takahiro, Sekiguchi, Masahiro, Kishikawa, Hidefumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249633/
https://www.ncbi.nlm.nih.gov/pubmed/35795121
http://dx.doi.org/10.1002/iju5.12426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249633/
https://www.ncbi.nlm.nih.gov/pubmed/35795121
http://dx.doi.org/10.1002/iju5.12426

Ejemplares similares